Protagonist Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTGX research report →
Companywww.protagonist-inc.com
Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
- CEO
- Dinesh V. Patel
- IPO
- 2016
- Employees
- 124
- HQ
- Newark, CA, US
Price Chart
Valuation
- Market Cap
- $6.49B
- P/E
- -57.24
- P/S
- 87.60
- P/B
- 10.02
- EV/EBITDA
- -47.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.45%
- Op Margin
- -192.36%
- Net Margin
- -154.88%
- ROE
- -17.76%
- ROIC
- -21.29%
Growth & Income
- Revenue
- $46.02M · -89.41%
- Net Income
- $-130,149,000 · -147.29%
- EPS
- $-2.05 · -145.86%
- Op Income
- $-158,127,000
- FCF YoY
- -69.32%
Performance & Tape
- 52W High
- $107.84
- 52W Low
- $45.05
- 50D MA
- $100.99
- 200D MA
- $82.54
- Beta
- 1.88
- Avg Volume
- 758.10K
Get TickerSpark's AI analysis on PTGX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | PATEL DINESH V PH D | other | 75,000 |
| May 12, 26 | PATEL DINESH V PH D | sell | 75,000 |
| May 12, 26 | PATEL DINESH V PH D | other | 75,000 |
| May 7, 26 | Giraudo Bryan | other | 12,000 |
| May 7, 26 | Giraudo Bryan | other | 24,000 |
| May 7, 26 | Giraudo Bryan | sell | 36,000 |
| May 8, 26 | Giraudo Bryan | sell | 5,130 |
| May 7, 26 | Giraudo Bryan | sell | 12,000 |
| May 8, 26 | Giraudo Bryan | sell | 6,000 |
| May 7, 26 | Giraudo Bryan | other | 24,000 |
Our PTGX Coverage
We haven't published any research on PTGX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PTGX Report →